Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2011-06-28
2011-06-28
Fetterolf, Brandon J (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S553000, C514S576000
Reexamination Certificate
active
07968531
ABSTRACT:
The invention relates to the use of 2,5-dihydroxybenzenesulfonic acid in the production of medicaments for the treatment of angiodependent diseases. More specifically, the invention relates to the use of the aforesaid compound and, in particular, the calcium and potassium salts thereof, for the treatment of two angiodependent diseases, which present a reduction in the apoptosis, namely cancer and psoriasis. The invention also discloses the antiproliferative, antimigratory, antiangiogenic and proapoptotic capacity of said family of compounds in non-quiescent cells. In addition, the invention details the potentiating effect of said compounds on known cytostatic medicines in the treatment of tumours and, specifically, on gliomas. The invention further relates to the therapeutic efficacy of said compounds, based on the combined antiproliferative, antiangiogenic and proapoptotic capacities thereof, in the treatment of chronic psoriatic plaques.
REFERENCES:
patent: 3954767 (1976-05-01), Esteve-Subirana
patent: 4115648 (1978-09-01), Esteve-Subirana
patent: 4837378 (1989-06-01), Borgman
patent: 4970202 (1990-11-01), Trigger
patent: 5519018 (1996-05-01), Matusch et al.
patent: 5698595 (1997-12-01), Boelle et al.
patent: 6281203 (2001-08-01), Touzan et al.
patent: 6664406 (2003-12-01), Coupland et al.
patent: 6787573 (2004-09-01), Nottet
patent: 2002/0143052 (2002-10-01), Lan-Hargest et al.
patent: 2003/0216418 (2003-11-01), Stogniew et al.
patent: 2004/0167222 (2004-08-01), Brooks et al.
patent: 2005/0175559 (2005-08-01), Dinardo et al.
patent: 2006/0258730 (2006-11-01), Allegretti et al.
patent: 2007/0032471 (2007-02-01), Torrens-Jover et al.
patent: 2007/0149618 (2007-06-01), Cuevas Sanchez et al.
patent: 2008/0113947 (2008-05-01), Cuevas Sanchez et al.
patent: 2008/0113948 (2008-05-01), Cuevas Sanchez et al.
patent: 2008/0114060 (2008-05-01), Cuevas Sanchez et al.
patent: 2008/0114063 (2008-05-01), Cuevas Sanchez et al.
patent: 2008/0114075 (2008-05-01), Cuevas Sanchez et al.
patent: 2008/0125485 (2008-05-01), Cuevas Sanchez et al.
patent: 2008/0125486 (2008-05-01), Cuevas Sanchez et al.
patent: 2009/0111779 (2009-04-01), Cuevas Sanchez et al.
patent: 0 204 987 (1991-11-01), None
patent: 1 719 509 (2005-11-01), None
patent: WO 96/17589 (1996-06-01), None
patent: WO 96/25159 (1996-08-01), None
patent: WO 2005/013962 (2005-02-01), None
patent: WO 2005/077352 (2005-08-01), None
patent: WO 2006/029484 (2006-03-01), None
patent: WO 2006/069806 (2006-07-01), None
Goodman et al. [Editors] “Chapter 198: Principles of Cancer Therapy.” Cecil's Textbook of Medicine (Twenty-First Edition, vol. 1). W.B. Saunders Company, 2000. pp. 1060-1074.
Actinic Keratosis and Other Precancers. The Skin Cancer Foundation. www.skincancer.org, 2008.
Arhanic, V., et al., “Attempts at Treating Rubeosis with Angioprotective Agents” Annals of the Dr. M. Stojanovic Hospital (1976) vol. 15, No. 2 pp. 120-123 (with English translation).
Banker et al. Modern Pharmaceutics, 3ed.; Marcel Dekker, New York, 1996, p. 596.
Barrett's disease: http://digestive-system.emedtv.com/barrett's-esophagus/casues-of-Barrett's-esophagus.html, Nov. 2006.
Brannon, http://dermatology.about.com/es/eczemadermatitis/a/atopictx.htm. Atopic Dermatitis Treatment.
Catalogo de especialidades farmaceuticas 1991, Consejo General de Colegios Oficiales De Farmaceuticos, Madrid, Spain, p. 674 Acnisdin and Acnisdin Retinoico entries (with summary in English).
Crohn's disease: http://cholitis.emedtv.com/crohn'sdisease/crohn's-disease-causes.html; (2008).
Cuevas et al. Dobesilate in the treatment of plaque psoriasis. Eur. J. Med. Res, 10, 373-376 (2005).
Cuevas, P. et al., Treatment of Basal Cell Carcinoma with Dobesilate, Journal of the American Academy of Dermatology, vol. 53, No. 3 (2005), pp. 526-527.
Definition of rosacea from American Heritage Medical Dictionary, 2007, www.freedictionary.com.
Divers et al. Curtis., 2004, vol. 73, No. 4, pp. 257-262 (Abstract attached).
Dormond O and Rüegg C, Inhibition of tumor angiogenesis by non-steroidal anti-inflammatory drugs: emerging mechanisms and therapeutic perspectives, Drug Resistance Updates (2002) 4, 314-321.
Gambichler T, et al., Cytokine mRNA expression in basal cell carcinoma, Arch Dermatol Res (2006) 298: 139-141.
Goldman et al. [editors] “Principles of Cancer Therapy.” Cecil's Textbook of Medicine (Twenty-First Edition, vol. 1). W.B. Saunders Company. 2000, pp. 1060-1074.
Graber, R., et al., Calcium Dobesilate protects human peripheral blood mononuclear cells from oxidation and apoptosis, Apoptosis, vol. 3, No. 1 (1998) pp. 41-49.
Hodge D, et al., The role of IL-6 and STAT3 in inflammation and cancer, European Journal of Cancer 41 (2005) 2502-2512.
Hornheide et al. British Journal of Dermatology, 2005, vol. 152, pp. 939-947.
Hornick, JL, et al. “A New Chemically Modified Chimeric TNT-3 Monoclonal Antibody Directed Against DNA for the Radioimmunotherapy of Solid Tumors” Cancer Biotherapy & Radiopharmaceuticals (1998) vol. 13, No. 4, pp. 255-268.
Jee S-H, et al., Interleukin-6 Induced Basic Fibroblast Growth Factor-Dependent Angiogenesis in Basal Cell Carcinoma Cell Line via JAK/STAT3 and PI3-Kinase/Akt Pathways, J Invest Dermatol (2004)123:1169-1175.
Jee S-H, et al., “Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases anti-apoptitic activity and tumorigenic potency”, Oncogene (2001) 20, 198-208.
Jee S-H, et al., “The Phosphotidyl Inositol 3-Kinase/Akt Signal Pathway is Invovled in Interleukin-6-mediated Mcl-1 Upregulation and Anti-apoptosis Activity in Basal Cell Carcinoma Cells”, J Invest Dermatol (20020 119: 1121-1127.
Johnson et al. British J. of Cancer, 2001, 84(10): 1424-1431.
Jordan VC. Nature Reviews: Drug Discovery, 2, 2003, p. 205.
Kaur et al. An open trial of calcium dobesilate in patients with venous ulcers and stasis dermatitis. International Journal of Dermatology. 2003, 42, 147-152.
Khawli, LA, et al. “Comparison of Recombinant Derivatives of Chimeric TNT-3 Antibody for the Radioimaging of Solid Tumors” Hybridoma and Hybridomics (2003) vol. 22, No. 1 pp. 1-10.
Lameynardie, S. et al., Inhibition of choroidal angiogenesis by calcium dobesilate in normal Wistar and diabetic GK rats, Eur J of Pharm, vol. 510 (2005) pp. 149-156.
Lens et al. Br. J. Nurs., 2008, vol. 17, No. 5, pp. 300-305 (Abstract attached).
Losa, G., et al., Prevention of Oxidation and Apoptosis in Human Peripheral Blood Mononuclear Cells Exposed to Calcium Dobesilate, Int'l J of Angiology, vol. 8 (1999) pp. 511-515.
Newell B, et al., “Comparison of the microvasculature of basal cell carcinoma and actinic keratosis using intravital microscopy and immunohistochemistry” British Journal of Dermatology 2003: 149; 105-110.
Nour, A.F., et al., Preliminary Clinical Study with Calcium Dobesilate in Fibrocystic Disease of the Breast, a pilot study, Acta Therapeutica, vol. 12, No. 3 (1986) pp. 233-241.
O'Grady A, et al.“COX-2 Expression Correlates with Microvessel Density in Non-Melanoma Skin Cancer from Renal Tranplant Recipients and Immunocompetent Individuals”, Hum Pathol (2004) 35: 1549-1555.
Oh C-K, et al., “Expression of Basic Fibroblast Growth Factor, Vascular Endothelial Growth Factor, and Thrombospondin-1 Related to Microvessel Density in Nonaggressive and Aggressive Basal Cell Carcinomas” Journal of Dermatology (2003) vol. 30: 306-313.
Remington's Pharmaceutical Sciences, pp. 420-425, 1980.
Ruiz, E. et al., Calcium Dobesilate Increases Endothelium- Dependent Relaxation in Endothelium-Injured Rabbit Aorta, Pharmacological Research, vol. 38, No. 5 (1998), pp. 361-366.
Rutkowski, Suzanne; Asthma Magazine, p. 9-12, Jul./Aug. 2001.
Sausville et al. (Cancer Research, 2006, vol. 66, pp. 3351-3354).
Schon et al. 2005, N. England J. Med. 352: 1899-912.
Sintov et al. Journal of Controlled Release, 2002, vol. 79, pp. 113-122.
Skov et al., “Basal cell carcinoma is associated with high TNF-χ polymorphism at position—308” Experim
Cuevas Sanchez Pedro
Gallego Guillermo Gimenez
Lozano Puerto Rosa María
Romero Garrido Antonio
Valverde Lopez Serafín
Action Medicines, S.L.
Fetterolf Brandon J
Frommer & Lawrence & Haug LLP
Pagonakis Anna
LandOfFree
Use of 2,5-dihydroxybenzenesulphonic acid in the production... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of 2,5-dihydroxybenzenesulphonic acid in the production..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of 2,5-dihydroxybenzenesulphonic acid in the production... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2732980